Development and validation of a nomogram for predicting immune-mediated colitis in lung cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study in China.

ABSTRACT:

Background

The increasing utilization of immune checkpoint inhibitors (ICIs) has led to a concomitant rise in the incidence of immune-related adverse events (irAEs), notably immune-mediated colitis (IMC). This study aimed to identify the clinical risk factors associated with IMC development in patients with lung cancer and to develop a risk prediction model to facilitate personalized treatment and care strategies.

Methods

The data collected included 21 variables, including sociodemographic characteristics, cancer-related factors, and routine blood markers. The dataset was randomly partitioned into a training set (70%) and a validation set (30%). Univariate and multivariate logistic regression analyses were conducted to identify independent predictors of IMC development. On t

SUBMITTER: Xu Q 

PROVIDER: S-EPMC11821966 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature